Tech Company Financing Transactions

Altair Therapeutics Funding Round

On 12/18/2007, Altair Therapeutics raised Series A investment from Forward Ventures, Thomas and McNerny & Partners.

Transaction Overview

Announced On
12/18/2007
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors

Forward Ventures (Joel Martin)

Thomas, McNerny & Partners (Pratik Shah)

Proceeds Purpose
Altair is developing AIR645 (ISIS 369645), an inhaled inhibitor of the IL-4/IL-13 signaling pathways for the treatment of asthma, which continues to be an area of unmet medical need. Altair in-licensed the compound from Isis Pharmaceuticals (NASDAQ:ISIS - News) and the two companies will collaborate to discover drugs directed to other promising targets for the treatment of respiratory conditions.

Company Information

Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
12555 High Bluff Dr. 310
San Diego, CA 92130
USA
Email Address
Overview
Altair is building a dedicated team, combining antisense drug discovery expertise with respiratory drug development expertise, to focus solely on the development and commercialization of antisense drugs for the treatment of asthma and other respiratory conditions.
Profile
Altair Therapeutics LinkedIn Company Profile
Social Media
Altair Therapeutics Company Twitter Account
Company News
Altair Therapeutics News
Facebook
Altair Therapeutics on Facebook
YouTube
Altair Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Joel Martin
  Joel Martin LinkedIn Profile  Joel Martin Twitter Account  Joel Martin News  Joel Martin on Facebook
Chief Financial Officer
Nicole DeBerg
  Nicole DeBerg LinkedIn Profile  Nicole DeBerg Twitter Account  Nicole DeBerg News  Nicole DeBerg on Facebook
Chief Medical Officer
Michael Hodges
  Michael Hodges LinkedIn Profile  Michael Hodges Twitter Account  Michael Hodges News  Michael Hodges on Facebook
Chief Scientific Officer
Susan Gregory
  Susan Gregory LinkedIn Profile  Susan Gregory Twitter Account  Susan Gregory News  Susan Gregory on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/18/2007: Ribbit venture capital transaction
Next: 12/18/2007: Verilogue venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record funding rounds that are announced publicly. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary